Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylo
本文档由 febday 分享于2020-03-01 23:03
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylo
下载文档
收藏
打印
君,已阅读到文档的结尾了呢~~